The EIF2D Knockout Huh-7 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population with disrupted EIF2D gene expression. This heterogeneous pool of Huh-7 cells harbors loss-of-function mutations, serving as a model to investigate non-canonical translation initiation. The polyclonal format mitigates clonal variation and off-target effects, providing a robust background for studying IRES-mediated translation. EIF2D ablation eliminates a key translation factor involved in re-initiation and IRES-dependent protein synthesis, enabling dissection of these pathways in hepatocellular carcinoma cells.
The Huh-7 cell line, derived from a hepatocellular carcinoma, is a well-differentiated hepatocyte-like model widely employed in liver cancer research, hepatitis C virus studies, and drug metabolism testing. Its epithelial origin and molecular fidelity to primary hepatocytes make it a suitable system for investigating oncogenic translation mechanisms and stress responses in hepatic cells.
EIF2D is a translation initiation factor that facilitates IRES-dependent and re-initiation mechanisms, associating with the 40S ribosomal subunit and factors like eIF3, eIF4G, and Ligatin. It is regulated by stress-sensing kinases GCN2 and PERK, and by mTOR-mediated growth signals through S6K and 4E-BP. Under stress, ATF4 induces EIF2D expression, which in turn drives IRES-mediated translation of oncogenic and survival mRNAs such as XIAP, BCL2, c-MYC, and Cyclin D1, linking cellular stress adaptation to cancer phenotypes.
In HCC, where EIF2D is often overexpressed, its knockout disrupts IRES-dependent synthesis of tumor-promoting proteins, potentially impairing proliferation, survival, and metastatic potential. By abolishing this non-canonical translation axis in Huh-7 cells, researchers can examine how loss of stress-responsive translation alters HCC cell behavior, providing insights into the role of EIF2D in liver carcinogenesis.
This polyclonal knockout model supports diverse assays: Western blotting and RT-qPCR for confirming EIF2D loss and downstream target changes; MTT and Annexin V assays for proliferation and apoptosis; migration/invasion tests; IRES luciferase reporters; polysome profiling; RNA-seq translatome analysis; and flow cytometry for cell cycle. These tools enable functional dissection of EIF2D in HCC, validation of therapeutic targets, and investigation of translation regulation in cancer. For further details, please contact Ascent Research.
